Biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) announced on Wednesday that it will work with Curia Global, a contract development and manufacturing organisation (CDMO), to provide formulation development services for Anixa's investigational breast cancer vaccine in preparation for its upcoming Phase 2 clinical trial.
The vaccine is being developed in collaboration with Cleveland Clinic.
Under the collaboration, Curia will support the development of a formulation designed to optimise the vaccine's stability, consistency, and suitability for clinical manufacturing. Anixa said that this work represents an important step in its preparations for Phase 2 and is intended to establish a formulation and development process capable of supporting future clinical studies and potential commercial production.
Anixa's investigational breast cancer vaccine is designed to stimulate the immune system to recognise alpha-lactalbumin, a protein expressed in many breast cancers. According to the company, the vaccine recently completed a Phase 1 clinical trial involving 35 women, meeting its primary endpoints and demonstrating a favourable safety and tolerability profile, with 74% of participants exhibiting protocol-defined immune responses. Anixa is preparing to advance the vaccine into Phase 2 clinical development to further evaluate its potential clinical benefits.
Onward Therapeutics closes Series B financing
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Apotex launches generic version of INLYTA in US market
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177